List of Excipients in Branded Drug LOVASTATIN

« Back to Dashboard

Generic Drugs Containing LOVASTATIN

Company	Ingredient	NDC	Excipient
Teva Pharmaceuticals USA Inc	lovastatin	0093-0926	BUTYLATED HYDROXYANISOLE
Teva Pharmaceuticals USA Inc	lovastatin	0093-0926	CELLULOSE, MICROCRYSTALLINE
Teva Pharmaceuticals USA Inc	lovastatin	0093-0926	FD&C YELLOW NO. 6
Teva Pharmaceuticals USA Inc	lovastatin	0093-0926	LACTOSE MONOHYDRATE
Teva Pharmaceuticals USA Inc	lovastatin	0093-0926	MAGNESIUM STEARATE
Teva Pharmaceuticals USA Inc	lovastatin	0093-0926	STARCH, CORN
Eon Labs Inc	lovastatin	0185-0070	BUTYLATED HYDROXYANISOLE

What are the Most Frequently-Used Excipients in LOVASTATIN?

# Of NDCs	Excipient
42	ANHYDROUS LACTOSE
1	BHA
115	BUTYLATED HYDROXYANISOLE
116	CELLULOSE, MICROCRYSTALLINE
1	CI 42090
4	D&C RED NO. 30
48	D&C YELLOW NO. 10

Lovastatin Excipient Strategy and Commercial Opportunities

Last updated: September 24, 2026

Lovastatin is an off-patent statin with limited commodity-tablet economics and a stronger opportunity profile in differentiated oral delivery. The active ingredient is a poorly water-soluble, lipophilic lactone that hydrolyzes in vivo to the active beta-hydroxy acid. Excipient selection should therefore target dissolution, chemical stability, dose uniformity, manufacturability, and patient usability rather than simply reducing tablet cost.

The most credible commercial opportunities are enhanced-bioavailability formulations, low-dose combination products, pediatric or dysphagia-friendly dosage forms, and products that improve food-effect control. A conventional immediate-release generic tablet remains technically straightforward but commercially difficult to differentiate.

What is lovastatin and why do excipients matter?

Lovastatin is a statin indicated with diet to reduce elevated total cholesterol and low-density lipoprotein cholesterol and to reduce coronary heart disease risk in appropriate patients. Merck originally marketed it as Mevacor. The compound is a semi-synthetic derivative of a fungal metabolite and is structurally related to simvastatin.

Lovastatin presents several formulation challenges:

Property	Formulation consequence
Poor aqueous solubility	Dissolution can limit absorption
Lipophilic structure	Surfactants, lipid systems, or particle-size reduction may improve exposure
Lactone ring	Hydrolysis can generate the active acid form during processing or storage
Low milligram dose	Blend uniformity and content uniformity are important
Food-dependent absorption	Meal composition can affect exposure
Oxidation sensitivity	Antioxidant and packaging strategy may be relevant
BCS II-type behavior	Solubility enhancement is commercially useful

The FDA label states that lovastatin is administered with food and that its systemic availability increases when taken with meals. The label also identifies active metabolites, including the beta-hydroxy acid form, which inhibits HMG-CoA reductase (FDA, 2023).

What excipients are used in approved lovastatin tablets?

Approved immediate-release lovastatin tablets generally use conventional solid-dose excipients. Product-specific compositions vary by manufacturer and strength.

Common excipient classes include:

Excipient class	Typical examples	Primary function
Diluent	Lactose, microcrystalline cellulose, dibasic calcium phosphate	Tablet mass and compressibility
Disintegrant	Pregelatinized starch, crospovidone, croscarmellose sodium	Tablet breakup
Binder	Povidone, starch, hydroxypropyl cellulose	Granule and tablet strength
Lubricant	Magnesium stearate, stearic acid	Ejection and processing
Glidant	Colloidal silicon dioxide	Powder flow
Surfactant	Sodium lauryl sulfate, polysorbates	Wetting and dissolution
Antioxidant	Butylated hydroxyanisole or related systems	Oxidative protection
Film coat	Hypromellose, polyethylene glycol, titanium dioxide, colorants	Protection, identification, swallowability

DailyMed listings show that excipient composition differs across lovastatin products. A development team cannot treat the excipient profile of one generic label as representative of every approved product (National Library of Medicine, 2024).

How should the core tablet platform be selected?

For a low-cost generic, direct compression can be attractive if the active pharmaceutical ingredient has suitable particle-size distribution and flow. Lovastatin’s low dose and poor solubility can make direct compression less robust than a wet- or dry-granulation process.

A practical platform is:

1. Micronized or tightly controlled particle-size lovastatin.
2. Microcrystalline cellulose or lactose for bulk and compressibility.
3. Crospovidone or croscarmellose sodium for rapid disintegration.
4. A low level of surfactant to improve wetting.
5. Magnesium stearate at a controlled concentration and blending time.
6. An opaque film coat if light or moisture protection is needed.

Excessive lubricant, especially prolonged magnesium-stearate blending, can reduce tablet wetting and dissolution. Surfactant selection also requires control of foaming, taste, impurity formation, and compatibility with the manufacturing process.

Which excipients improve lovastatin dissolution and bioavailability?

The strongest technical opportunity is to increase the dissolution rate without compromising chemical stability.

Surfactant-based systems

Surfactants can reduce interfacial tension and improve wetting of lovastatin particles. Candidate materials include sodium lauryl sulfate, poloxamers, polysorbates, and certain nonionic surfactants.

Commercial limitations include:

• Potential gastrointestinal intolerance at higher levels.
• Taste and mouthfeel problems in dispersible or liquid dosage forms.
• Possible changes in dissolution during storage.
• Regulatory scrutiny of unusual excipient levels.
• Scale-up sensitivity in granulation and drying.

Surfactants are most useful as part of a broader formulation design rather than as the sole solubility strategy.

Amorphous solid dispersions

Amorphous solid dispersions can increase apparent solubility by dispersing lovastatin in a polymeric carrier. Potential polymers include hypromellose, hypromellose acetate succinate, polyvinylpyrrolidone, copovidone, and Soluplus-type materials.

The primary risks are recrystallization, residual solvent, hygroscopicity, and manufacturing complexity. A solid dispersion is commercially attractive only if it produces a clinically or regulatory-relevant benefit over a conventional generic tablet.

Nanocrystals and particle-size reduction

Nanocrystal or micronized lovastatin systems can improve dissolution through higher surface area. Stabilizers may include poloxamers, cellulose derivatives, or other polymeric dispersants.

This route can support a lower-dose tablet, an orally disintegrating tablet, or a reduced-food-effect product. The development burden includes particle-size control, aggregation prevention, equipment qualification, and demonstration that the finished product remains equivalent over shelf life.

Lipid-based formulations

Self-emulsifying drug delivery systems, microemulsions, and lipid suspensions are technically plausible because lovastatin is lipophilic. Excipients may include medium-chain triglycerides, mono- and diglycerides, PEG-based surfactants, and co-solvents.

Lipid systems can improve solubilization but create manufacturing and packaging challenges. They are more commercially credible in softgels, liquid-filled hard capsules, or oral suspensions than in a standard compressed tablet.

Cyclodextrins and complexing agents

Cyclodextrin inclusion complexes may improve apparent aqueous solubility. The commercial value depends on the dose, complexation efficiency, excipient burden, and evidence of improved exposure or reduced variability. Cyclodextrin systems can be expensive relative to the value of generic lovastatin and may be difficult to justify without a new dosage form or clinical advantage.

What excipient strategy best addresses lovastatin stability?

Lovastatin stability work should focus on hydrolysis, oxidation, moisture, light, and interaction with processing conditions.

Chemical stability priorities

The development program should evaluate:

• Lactone hydrolysis to lovastatin acid.
• Oxidative degradation of the statin structure.
• Moisture uptake by polymers and disintegrants.
• Residual water after granulation or spray drying.
• Light exposure during manufacturing and storage.
• Interaction between antioxidants and packaging materials.
• Degradation caused by excessive heat or shear.

A formulation that produces fast dissolution but accelerates conversion or degradation is not commercially viable.

Antioxidant selection

Antioxidants such as butylated hydroxyanisole have been used in statin formulations, but their inclusion must be justified through compatibility and stability data. The development team should compare:

• Butylated hydroxyanisole.
• Butylated hydroxytoluene.
• Tocopherols.
• Ascorbate-based systems.
• Chelating agents where trace metals contribute to degradation.

The preferred antioxidant is not necessarily the most effective in a simple binary mixture. Its performance depends on the full formulation, oxygen exposure, tablet coating, bottle or blister system, and storage humidity.

Packaging strategy

Packaging can provide as much commercial value as an excipient change. Options include:

Packaging approach	Best use
High-density polyethylene bottle with desiccant	Standard tablets and cost-sensitive products
Aluminum-aluminum blister	High moisture and light protection
PVC/PVdC blister	Lower-cost unit-dose packaging
Opaque bottle or blister	Light-sensitive formulation
Unit-dose blister	Adherence programs and institutional dispensing

Packaging claims should be supported by stability data rather than used as a substitute for formulation optimization.

What formulations are commercially protected or differentiated?

Lovastatin’s original composition-of-matter protection has expired, and conventional immediate-release tablets are generic products. The commercial value therefore depends on formulation differentiation, regulatory status, manufacturing efficiency, or combination therapy.

Potential differentiated dosage forms include:

Dosage form	Commercial rationale	Main technical barrier
Immediate-release tablet	Low-cost generic supply	Minimal differentiation
Orally disintegrating tablet	Dysphagia and adherence	Taste masking and moisture sensitivity
Chewable tablet	Pediatric or swallowing convenience	Taste, dose uniformity, mouthfeel
Oral suspension	Pediatric or geriatric use	Physical stability and preservative system
Softgel	Lipid solubilization	Encapsulation, leakage, stability
Extended-release tablet	Reduced dosing frequency	Clinical benefit and dose dumping control
Combination tablet	Cardiovascular risk management	Compatibility and regulatory pathway
Amorphous dispersion tablet	Enhanced dissolution	Physical stability
Nanocrystal product	Faster dissolution and possible food-effect reduction	Manufacturing and equivalence

The strongest near-term opportunity is usually a formulation that solves a specific patient or payer problem. A new excipient combination alone is unlikely to support premium pricing unless it produces a measurable clinical, adherence, or pharmacokinetic benefit.

What is the FDA regulatory status of lovastatin?

Lovastatin is an FDA-approved small-molecule drug available in generic tablets. The FDA-approved reference product is Mevacor, while Altoprev was an extended-release lovastatin product. Lovastatin is not a biologic, so biosimilar regulation does not apply.

Regulatory issue	Lovastatin position
FDA pathway	Abbreviated New Drug Application for standard generics
Reference product	Mevacor
Small-molecule generic status	Established
Biosimilar risk	Not applicable
New formulation pathway	NDA, 505(b)(2), or applicable abbreviated pathway depending on product
Orange Book relevance	Reference-product patents and exclusivity are generally historical for the core product
Current exclusivity profile	No meaningful composition-of-matter exclusivity for conventional lovastatin tablets

The FDA Orange Book should be checked for current listed patents and exclusivity tied to the specific reference product and dosage form. For a standard generic lovastatin tablet, the central regulatory task is bioequivalence and CMC control, not freedom from a live basic patent (FDA, 2024a).

When did lovastatin lose patent exclusivity?

The core lovastatin patent estate expired decades ago. The original Merck patent covering lovastatin was filed in the late 1970s and expired in the 1990s under the pre-1995 U.S. patent-term framework. Any remaining patent risk is therefore more likely to involve a later formulation, manufacturing process, delivery system, or combination claim than lovastatin itself.

What is the Paragraph IV risk for lovastatin?

Paragraph IV litigation was relevant when generic applicants first challenged brand lovastatin patents. That risk has diminished substantially for conventional immediate-release tablets because the core patents and historical exclusivity periods have expired.

Current Paragraph IV exposure would arise mainly from:

• A newly listed formulation patent.
• A patent covering a specific extended-release system.
• A method-of-use patent tied to a narrow indication.
• A patent covering a particular combination product.
• A patent covering a drug-device or specialized delivery system.

Generic applicants still need to review the current Orange Book and patent certifications for the exact reference-listed drug. A historical absence of litigation does not eliminate product-specific patent review.

What manufacturing and intellectual-property barriers remain?

The principal barriers are technical and commercial rather than basic molecule patents.

Manufacturing barriers

A developer may need to control:

• API particle-size distribution.
• Polymorphic or solid-state form.
• Blend uniformity at low dose.
• Granulation endpoint.
• Residual moisture.
• Dissolution after scale-up.
• Degradation during coating.
• Content uniformity across commercial batches.

For advanced delivery systems, additional barriers include spray-drying reproducibility, nanocrystal particle-size control, lipid fill compatibility, and long-term physical stability.

Intellectual-property barriers

Potentially protectable elements include:

• Specific polymer-to-drug ratios.
• Stabilized amorphous dispersions.
• Particle-size ranges.
• Solid-state forms.
• Taste-masked compositions.
• Extended-release matrices.
• Combination products.
• Manufacturing processes that reduce degradation.
• Packaging and moisture-control systems, where claim scope is meaningful.

A formulation patent has greater commercial value when it is difficult to design around and when the product has a realistic premium or market-access advantage. A narrow excipient ratio with no demonstrated clinical or manufacturing benefit is usually weak as a licensing asset.

How strong is the lovastatin patent estate?

The core patent estate is weak for new entrants because the molecule is long off-patent. The estate can be characterized as follows:

Asset category	Current strategic value
Original molecule patents	Expired
Standard immediate-release tablet claims	Low
Historical extended-release claims	Product-specific; generally limited by age and market status
New formulation patents	Potentially meaningful if clinically differentiated
Manufacturing patents	Moderate if they lower cost or improve stability
Method-of-use patents	Limited unless tied to a distinct approved indication
Combination-product patents	Potentially stronger, depending on components and market
Biosimilar exclusivity	Not applicable

The highest-value IP opportunity is not a broad lovastatin patent. It is a narrow, defensible delivery platform linked to measurable product performance.

Which commercial opportunities are most attractive?

1. Low-cost, high-reliability generic supply

This is the lowest-risk opportunity but also the lowest-margin segment. Differentiation can come from robust dissolution, fewer recalls, low defect rates, and reliable supply rather than a novel excipient system.

2. Orally disintegrating or chewable lovastatin

A dysphagia-friendly product could target older adults and patients who have difficulty swallowing tablets. The major development issue is taste masking. Ion-exchange resins, polymeric coatings, sweeteners, flavors, and buffering agents may be required.

3. Pediatric formulation

Lovastatin is not a natural first-choice pediatric product opportunity, but a liquid or dispersible formulation could have value in specialized lipid disorders if supported by an appropriate regulatory and clinical strategy. Preservative compatibility, dosing accuracy, and acceptability would determine commercial viability.

4. Combination products

Combination therapy with other cardiovascular agents could improve adherence. Examples could include lovastatin with antihypertensive or antiplatelet agents, subject to clinical and regulatory justification.

The formulation must address dose flexibility, drug-drug compatibility, dissolution of each active ingredient, and whether a fixed-dose combination has a clear treatment rationale.

5. Enhanced dissolution or reduced food effect

A formulation that reduces exposure variability or permits administration without a meal could have a stronger value proposition than a standard generic. Demonstrating this benefit requires comparative pharmacokinetic data and a regulatory pathway that supports the proposed labeling.

6. Contract development and manufacturing

Lovastatin can support a platform offering for generic manufacturers that need:

• Low-dose blend uniformity.
• Stability-enhancing excipient systems.
• Spray-dried dispersion manufacturing.
• Lipid-filled capsules.
• Pediatric liquids.
• Unit-dose packaging.

The commercial opportunity is broader when the excipient platform can be applied to other poorly soluble APIs.

How does lovastatin compare with simvastatin and atorvastatin?

Factor	Lovastatin	Simvastatin	Atorvastatin
Core patent status	Long expired	Long expired	Core patents expired
Drug form	Lactone prodrug	Lactone prodrug	Active acid
Solubility challenge	High	High	High
Generic competition	High	High	Very high
Formulation differentiation	Possible but difficult	Similar opportunity	Larger market but more crowded
Food-related considerations	Important	Important	Less dependent on meal timing
Premium formulation potential	Niche	Niche	More commercially attractive due to market size
Biosimilar risk	None	None	None

Atorvastatin has a larger commercial base, while lovastatin may offer a lower-cost development and manufacturing platform. Simvastatin is the closest formulation comparator because both compounds are lactone prodrugs with similar solubility and hydrolysis considerations.

What generic launch scenarios exist for lovastatin?

A new entrant has four practical launch scenarios:

Scenario	Product	Market position
Commodity generic	Conventional tablet	Lowest development risk and margin
Quality-differentiated generic	Better dissolution, packaging, or supply reliability	Moderate differentiation
Specialty dosage form	ODT, chewable, liquid, or softgel	Niche premium opportunity
505(b)(2)-type reformulation	New delivery or food-effect profile	Higher investment and regulatory risk

Geographic opportunities vary. The United States offers a mature generic market with established FDA requirements. Europe and other regulated markets require region-specific excipient acceptability, bioequivalence, and labeling review. Emerging markets may place greater weight on cost, local manufacturing, and stable supply than on advanced delivery technology.

What revenue exposure and market risks should investors assess?

Lovastatin revenue exposure is generally limited by:

• Multiple generic competitors.
• Low unit pricing.
• Mature prescribing patterns.
• Competition from atorvastatin and rosuvastatin.
• Limited willingness to pay for a reformulated legacy statin.
• Substitution by pharmacy benefit managers and public purchasers.

A differentiated formulation must therefore target a defined segment. A product that only changes excipients without improving adherence, dosing convenience, bioavailability, stability, or cost will have weak pricing power.

Key Takeaways

• Lovastatin is a long-off-patent, poorly soluble lactone statin with conventional generic competition.
• Excipient strategy should focus on dissolution, hydrolysis control, oxidation protection, low-dose uniformity, and food-effect management.
• Suitable technologies include micronization, surfactant systems, amorphous solid dispersions, nanocrystals, lipid formulations, and patient-friendly dosage forms.
• The core molecule has no meaningful current composition-of-matter exclusivity.
• Paragraph IV risk is mainly relevant to later formulation, combination, or delivery patents.
• Biosimilar risk does not apply because lovastatin is a small molecule.
• The best commercial opportunities are differentiated dosage forms, improved administration, fixed-dose combinations, and reusable solubility-enhancement platforms.
• A conventional tablet can be profitable only with strong cost control, reliable supply, or a defensible market-access advantage.

FAQs

Can lovastatin be formulated as an oral suspension?

Yes. An oral suspension would require particle-size control, wetting agents, suspending polymers, preservatives where appropriate, taste masking, and validated dose uniformity. Physical stability and patient acceptability are the main development risks.

Is lactose suitable for lovastatin tablets?

Lactose is commonly used as a tablet diluent and can be suitable when compatibility, patient labeling, and moisture stability are controlled. Lactose-free formulations can use microcrystalline cellulose, mannitol, dibasic calcium phosphate, or other alternatives.

Can a new lovastatin excipient combination receive patent protection?

Potentially. Protection would depend on novelty, non-obviousness, enablement, and meaningful claim scope. A simple substitution of one conventional diluent or lubricant is unlikely to create strong protection without unexpected performance.

Would a lovastatin nanocrystal product require new clinical trials?

Not necessarily. The required evidence would depend on the formulation, proposed labeling, exposure differences, regulatory pathway, and whether the product is positioned as a bioequivalent generic or a clinically differentiated reformulation.

Does lovastatin have a biosimilar market?

No. Biosimilars apply to biological products. Lovastatin is regulated as a small-molecule drug, so competitive entry occurs through generic and reformulation pathways.

References

1. U.S. Food and Drug Administration. (2023). Mevacor (lovastatin) prescribing information.
2. U.S. Food and Drug Administration. (2024a). Approved drug products with therapeutic equivalence evaluations: Orange Book.
3. National Library of Medicine. (2024). DailyMed: Lovastatin product labeling.
4. U.S. Food and Drug Administration. (2024b). Inactive ingredient database.
5. PubChem. (2024). Lovastatin compound summary. National Center for Biotechnology Information.